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Vitamin D improves endothelial 
dysfunction and restores myeloid 
angiogenic cell function via reduced 
CXCL-10 expression in systemic 
lupus erythematosus
John A Reynolds1,2, Sahena Haque3, Kate Williamson2,4, David W Ray5, M Yvonne Alexander2,6 
& Ian N Bruce1,7
Patients with systemic lupus erythematosus (SLE) have accelerated cardiovascular disease and 
dysfunctional endothelial repair mechanisms. Myeloid angiogenic cells (MACs), derived from circulating 
monocytes, augment vascular repair by paracrine secretion of pro-angiogenic factors. We observed that 
SLE MACs are dysfunctional and secrete pro-inflammatory cytokines. We also found that the vitamin 
D receptor was transiently expressed during MAC differentiation and that in vitro, calcitriol increased 
differentiation of monocytes into MACs in both SLE and in a model using the prototypic SLE cytokine, 
interferon-alpha. The active form of vitamin D (calcitriol) restored the SLE MAC phenotype towards that 
of healthy subjects with reduced IL-6 secretion, and normalised surface marker expression. Calcitriol 
also augmented the angiogenic capacity of MACs via the down-regulation of CXCL-10. In SLE patients 
treated with cholecalciferol for 12 weeks, the improvement in endothelial function correlated with 
increase in serum 25(OH)D concentrations independently of disease activity. We also show that MACs 
were able to positively modulate eNOS expression in human endothelial cells in vitro, an effect further 
enhanced by calcitriol treatment of SLE MACs. The results demonstrate that vitamin D can positively 
modify endothelial repair mechanisms and thus endothelial function in a population with significant 
cardiovascular risk.
Systemic lupus erythematosus (SLE) is an autoimmune, systemic, inflammatory disorder predominantly affecting 
women. Patients with SLE have a significantly increased risk of cardiovascular disease which is not explained by 
traditional risk factors1. Endothelial dysfunction and the loss of endothelial integrity precede the development of 
atherosclerosis2 and endothelial dysfunction, assessed by flow-mediated dilatation (FMD), is an established risk 
factor for future cardiovascular events in the general population3.
Circulating cells, including myeloid angiogenic cells (MACs), contribute to vascular homeostasis via the par-
acrine secretion of potent angiogenic factors4. In animal models, inhibition of MAC function is associated with 
reduced re-endothelialisation following carotid artery injury5. In addition, infusion of peripheral blood-derived 
MACs contribute directly to vascular repair post-myocardial infarction6. In vitro models of important MAC 
functions such as migration and angiogenesis, offer an opportunity to investigate novel vasculoprotective agents, 
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including vitamin D. In the context of SLE, MACs are dysfunctional due, in part, to effects of interferon-alpha 
(IFNα )7,8. Furthermore, activated IFNα pathways are associated with both active disease and endothelial dys-
function in SLE patients9, supporting the use of IFNα treatment of MACs as a useful model of SLE.
Epidemiological studies show that vitamin D deficiency is associated with future cardiovascular events in the 
general population10 and correlates with the presence of endothelial dysfunction11 and carotid intima-medial 
thickness12. Of note, LDLR−/−VDR−/− mice develop increased atherosclerosis independent of raised serum cho-
lesterol levels13. Vitamin D deficiency is highly prevalent in SLE, due in part to the photosensitive nature of the 
disease14–16 and we have previously established that in SLE patients, arterial stiffness is associated with vitamin 
D status17.
High dose cholecalficerol supplementation has been shown to improve endothelial function over a short time 
course in some populations18–21, however the mechanism underpinning the improvements in endothelial func-
tion by vitamin D in SLE is unknown.
In vitro studies do not clearly support a direct positive effect of the active form of vitamin D (calcitriol) on 
mature endothelial cells22,23, however, in contrast, myeloid cell function has been shown to be modulated by 
calcitriol treatment in vitro24, suggesting that MAC responses may also be targeted by vitamin D. Recently Wong 
et al. (2014) demonstrated that the number of circulating CD45−CD117+Sca1+Flk1+cells (a putative precursor of 
MACs) was increased in 6 healthy subjects following treatment with 4,000 IU/day cholecalciferol. Furthermore, 
in 2 models of murine vessel wall injury, calcitriol promoted endothelial repair and angiogenesis; a phenomenon 
mediated via increased SDF-1 expression in the damaged vessel and increased MAC chemotaxis25.
This study describes the use of in vitro models of MAC function and the effectiveness of calcitriol to restore 
SLE MACs phenotype, augment the angiogenic capacity of MACs and to positively modulate the paracrine reg-
ulation of endothelial nitric oxide synthase (eNOS). The clinical relevance of these observations is investigated in 
terms of improvements in endothelial function in cholecalciferol-treated SLE patients.
Results
MACs from SLE patients are more numerous but show impaired function. MACs were isolated 
from blood samples taken from SLE patients and healthy controls (HCs) and cultured for 7 days. The yield of 
MACs was significantly higher from SLE patients compared to healthy controls (Fig. 1a). The colony-forming 
unit (CFU) capacity of MACs was investigated as a global measure of MAC function. CFUs were studied in an 
additional cohort of n = 38 SLE patients and n = 27 HCs none of whom received cholecalciferol. The median 
(IQR) age was 53 (46, 58) and 43 (28, 55) years respectively Compared to healthy control MACs, we observed an 
impaired capacity of SLE MACs to generate colonies in terms of both number (median number 5.4 vs 9.8 per field, 
Figure 1. SLE MACs are dysfunctional in vitro. (a) Patients with SLE have an increased number of MACs 
after 7 days compared to HCs (n = 9 controls and n = 30 SLE patients). (b) Representative image of a CFU from 
a healthy subject. Scale bar =100 μm. The number of CFUs (c) and large colonies (>50 cells) (d) is significantly 
lower in SLE patients compared to HCs (n = 27 controls and n = 38 SLE patients). (e) The migratory capacity of 
SLE MACs towards SDF-1α is impaired in SLE. The graph shows the relative chemotaxis to SDF-1α compared 
to chemokinesis in n = 6 healthy subjects and n = 10 controls. Data show the mean number of MACs (over 3 
random field per subject) or CFUs). *P < 0.05, **P < 0.01, ***P < 0.001 by Mann-Whitney U-test (a,c) and 
(d), and two-tailed t-test (e).
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p = 0.0017, Fig. 1c) and size where the colonies formed were smaller using SLE cells (median number of colonies 
>50 cells per colony 0.0 vs. 3.0 per field, p = 0.0002). This difference in CFU number remained significant after 
adjustment for age (β [SE] 0.40 [2.49], p = 0.002). The migratory capacity of SLE MACs towards SDF-1α was also 
significantly impaired when compared to healthy controls (Fig. 1d). On further analysis there was no difference 
in migration between MACs from 25(OH)D deficient or replete SLE patients (not shown). These results demon-
strate that whilst MAC number may be increased in this SLE population, the function is globally impaired.
Calcitriol increases the differentiation of myeloid progenitor cells into MACs. We isolated healthy 
MACs and incubated them in the presence of IFNα 2b to determine whether this could replicate the SLE phe-
notype in vitro. Of note, a dose-response to IFNα 2b (0.01–50 ng/ml) showed a marked relative reduction in the 
number of MACs present at day 8 (Fig. 2a), therefore, a low dose of IFNα 2b (0.01 ng/ml) was used for further 
studies to retain cell viability. IFNα 2b (0.01 ng/ml) treatment had no effect on any of the following parameters; i) 
the migratory capacity of MACs, ii) the adhesion of MACs to activated endothelium, or iii) the angiogenic capac-
ity of MACs (data not shown), suggesting the abnormal phenotype of SLE MACs cannot be attributed to exposure 
of MACs to interferon-alpha in isolation.
However, the reduced survival of HC MACs in the presence of IFNα 2b in vitro offered a model to investigate 
the direct effects of calcitriol, without concerns regarding the heterogeneity of SLE patients. In this model, calci-
triol increased MAC number in a dose-responsive manner (Fig. 2b). This effect was significant at 1 nM concen-
tration with an EC50 of 4.8 nM.
In vitamin D deficient (but not replete) SLE patients, culture with 10 nM calcitriol enhanced the expansion 
of MACs; the number of MACs (per random field) in deficient patients increased from mean (sd) 159.1 (75.3) to 
194.5 (44.6) (p = 0.044) (Fig. 2c). The increased cell numbers in response to calcitriol was inversely related to the 
number of MACs in the absence of calcitriol (r = − 0.697, p = 0.007), demonstrating that the increase in MACs in 
response to calcitriol is limited by a threshold effect (Fig. 2d).
Calcitriol restores MAC phenotype in SLE. Expression of the VDR in PBMCs was similar to that 
detected in HAoECS (Fig. 3a). VDR expression markedly increased in MACs by day 2 (15.6-fold), declined 
by day 4 (5.1-fold from baseline), and returned to baseline (PBMC) levels by day 8. The culture of SLE MACs 
Figure 2. Calcitriol increases MAC number in SLE and in an IFN-model. (a) IFNα 2b decreases the number 
of HC MACs in a dose-dependent manner (pooled from n = 5 healthy controls). (b) In a model of HC MACs 
treated with 0.1 ng/ml IFNα 2b, calcitriol increases MAC number in a dose-dependent manner (n = 5 healthy 
subjects). The EC50 for this effect is 4.8 nM. (c) 10 nM calcitriol increases the number of MACs from vitamin D 
deficient but not vitamin D replete SLE patients (paired samples of n = 14 deficient patients and n = 8 replete). 
(d) The change in SLE MAC number (deficient patients) in response to calcitriol is negatively correlated with 
the number of untreated MACs (n = 14 patients). (a,b) show the mean ( ± SE) relative number of MACs 
compared to vehicle control. (c) shows the mean number of MAC and the bar shows mean for the group. (d) 
shows the Spearman correlation coefficient. *P < 0.05, ***P < 0.001, ****P < 0.0001 by paired t-test.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:22341 | DOI: 10.1038/srep22341
with calcitriol resulted in a morphological change in appearance, from the typical “fried egg” morphology of 
macrophages to a more rounded phenotype (Fig. 3b). In order to determine whether the architectural changes 
observed in the cells represent phenotypic shift in the MACs, we performed a gene ontology analysis of the data-
set produced by Kupfer et al. (2013), comparing gene expression in healthy PBMCs in response to 10 nM calcitriol 
for 24 hours (see supplement for details)26. There was reduced expression of genes with roles in “haematological 
system development and function”. Within this group, there was significant down regulation of genes associated 
with phagocyte activation, movement, chemotaxis and inflammatory response.
These data were verified using qRT-PCR and compared to HC MACs, SLE MACs showed significantly 
increased expression of the general macrophage marker CD68, and the M2-specfic marker MRC1 (CD206) com-
pared to the HC counterpart. When SLE MACs were incubated in the presence of calcitriol, expression of these 
markers returned towards the more normal phenotype observed in HC MACs (Fig. 3c).
Furthermore in the healthy PBMC dataset from Kupfer et al., calcitriol down-regulated the expression of a 
number of genes related to macrophage differentiation including IL-6, IL-15, CD40 and MMP-9. To validate 
this data, using IL-6 as an exemplar, we measured the secretion of IL-6 by SLE MACs in response to calcitriol 
using ELISA. We found that IL-6 secretion by clacitriol-treated SLE MACs was significantly lower compared to 
untreated cells (24.9[11.8] vs. 50.7[45.0]pg/ml, p = 0.0002) (Fig. 3d). These data suggest that calcitriol may restore 
the activation status of SLE macrophages, towards that of HC, resulting in lower expression of pro-inflammatory 
cytokines.
Angiogenic capacity of MACs is increased by calcitriol via down-regulation of CXCL-10. We 
confirmed that HC MACs have a pro-angiogenic capacity in vitro using a Matrigel angiogenesis model (see 
supplementary data, Fig. S1). The conditioned media from SLE MACs expanded in the presence of calcitriol 
(MAC-D) had significantly augmented angiogenic capacity (Fig. 4a). This was not due to the presence of cal-
citriol in the conditioned media, as calcitriol alone did not have an effect on endothelial network formation. 
There was no association between the change in MAC number and the increase in angiogenic capacity, suggest-
ing that calcitriol may modify the MAC secretome in order to promote angiogenesis. Bioinformatics analysis of 
PBMC response to calcitriol (as described above) demonstrated up-regulation of 8 pro-angiogenic molecules, and 
down-regulation of 8 anti-angiogenic molecules (see supplementary data tables S2 and S3).
We postulated that CXCL-10 (IP-10) may be important, as this cytokine was increased in the serum of SLE 
patients and has anti-angiogenic functions in an in vitro Human Umbilical Vein Endothelial Cell (HUVEC) 
Figure 3. Calcitriol modulates MAC phenotype towards reduced differentiation. (a) Immunoblotting of 
the VDR shows increased but transient expression in MACs compared to PBMCs and HAoECs. (b) Calcitriol 
changes the morphology of SLE MACs. Image shows LDL-uptake by cells (red). Scale bar = 50 μm. (c) qRT-
PCR analysis shows increased expression of surface markers in SLE MACs which return towards HC levels of 
expression when cultured with calcitriol (n = 4 healthy and n = 5 SLE subjects). (d) Calcitriol reduces secretion 
of the pro-inflammatory cytokine IL-6 by SLE MACs (n = 10 subjects). Data in (c,d) show the mean (± SE). 
**P < 0.01, ***P < 0.001, ****P < 0.0001 by 2-way ANOVA (c) and paired t-test (c).
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model27. In keeping with the data above showing reduced expression of IL6 in response to calcitriol, we found 
that MACs incubated in the presence of calcitriol (MAC-D), secreted lower concentrations of CXCL-10 (36.0 
[91.9] vs. 12.9[36.0]pg/ml, p = 0.0006) (Fig. 4b). An anti-CXCL-10 neutralising antibody was then used to block 
the anti-angiogenic effects of CXCL-10 produced by SLE MACs in the angiogenesis model. In the angiogenesis 
assay, anti-CXCL-10 antibodies attenuated the pro-angiogenic effect of vitamin D (Fig. 4c). In other models of 
MAC function, SLE MACs expanded in the presence of calcitriol (MAC-D) showed no difference in migration 
or adhesion (not shown). These results demonstrate that calcitriol increases the angiogenic capacity of MACs by 
the down-regulation of CXCL-10.
Vitamin D-treated SLE MACs modulate eNOS expression. The conditioned media from SLE MACs 
had no effect on eNOS expression in resting HAoECs (not shown). Tumour necrosis factor-alpha (TNFα ) was 
therefore used to activate the endothelial cells and down-regulate eNOS. In the presence of TNFα , MAC media 
had a small protective effect on NOS3 expression which was further increased in the presence of MAC-D media 
(Fig. 5a). There was a good correlation of expression at the protein level, where MAC-D enhanced eNOS protein 
expression compared to SLE MACs (Fig. 5b,c). Calcitriol alone had no effect on NOS3 expression (transcript or 
protein level).
Figure 4. Calcitriol increases the angiogenic capacity of SLE MACs but not MAC migration or adhesion. 
(a) Angiogenic capacity of MACs in the Matrigel model is increased by isolating MACs with calcitriol whilst 
calcitriol alone is not pro-angiogenic (n = 8 patients). (b) Calcitriol reduces the expression of CXCL-10 by 
SLE MACs (n = 10 patients). (c) Blockade of CXCL-10 increases the angiogenic capacity of SLE MACs and 
attenuates the effect of culture with calcitriol (n = 3 experiments). Columns show means (± SE). *P < 0.05, 
***P < 0.001 by ratio paired t-tests where indicated.
Figure 5. MAC regulation of endothelial cell eNOS expression. (a) TNFα down-regulates eNOS transcript 
expression in HAoECs. Calcitriol increased the ability of MAC-conditioned media (MAC-D) to partially  
inhibit this down-regulation whilst MACs cultured without vitamin D had no significant effect (MAC).  
(b) Representative immunoblot of the change in eNOS expression in HAoEC. (c) eNOS protein expression 
shows the same pattern as the transcript with greatest effect with vitamin D-treated MACs but no effect of 
calcitriol in isolation. (a,c) show results from n = 3 and n = 4 patients respectively. *P < 0.05, **P < 0.01 by ratio 
paired t tests.
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In summary, the in vitro data presented, demonstrate that calcitriol modifies the phenotype of SLE MACs, 
restoring them towards those of healthy controls, and augments both the angiogenic capacity of MACs and the 
paracrine regulation of eNOS.
Vitamin D improves endothelial function in SLE patients. In our clinical cohort we compared vita-
min D deficient (25(OH)D < 20 ng/ml) to vitamin D replete (25(OH)D > 30 ng/ml) patients. Vitamin D deficient 
patients were younger (median [IQR] age 46.9 [44.5, 57.6] vs. 57.8 [52.7, 64.6] years respectively, p = 0.007), were 
more likely to have a history of renal disease (7/22 [71.8%] vs. 1/18 [5.6%], p = 0.039) and to be taking corticoster-
oids or other immunosuppressive therapies (13/22 [59.1%] vs. 3/18 [16.7%], p = 0.006) (Table 1). Systolic blood 
pressure was higher in the deficient group (median [IQR] 124 [120,135] vs. 139 [133, 150 mmHg], p = 0.023) but 
there were no other differences in other cardiovascular risk factors or SLE disease activity (not shown).
Compared to vitamin D replete SLE patients, deficient patients showed a significant increase in 25(OH)D 
following 3 months of cholecalciferol treatment (26.8 [18.3, 35.0] vs. − 0.62 [− 3.99, 2.63]ng/ml, p < 0.0001). The 
change in serum 25(OH)D was subject to a threshold effect with a negative correlation between the change in 
25(OH)D and the pre-treatment 25(OH)D level (r = − 0.675, p < 0.001) (Fig. 6a). Vitamin D treatment had no 
clinically significant effect on serum calcium (median [IQR] change of 0.06 [− 0.05, 0.15] vs. − 0.03 [− 0.10, 0.03]
mmol/l, p = 0.053).
Cholecalciferol increased the number of MACs over 3 months, with an absence of this effect in the control 
group (Fig. 6b). There was a trend towards improvement in endothelial function in the treated group (ED/EI 
47.0% to 62.0%, p = 0.190) but not the replete group (ED/EI 46.2% to 38.5%, p = 0.684) (Fig. 6c). Post-treatment 
endothelial function was similar to that of a cohort of healthy controls (ED/EI 62.0% vs. 54.2%). There was a 
significant correlation between the change in 25(OH)D (ΔvitD) and change in endothelial function (ΔEF in the 
treated group (r = 0.650, p = 0.006) but not the replete group (Fig. 6d). In an ordered logistic regression model, 
ΔEF was associated with ΔvitD after adjustment for age (OR 1.12 [1.02, 1.24], p = 0.017).
Demographics Deficient (n = 22) Replete (n = 18) p
Age (years) 46.9 (44.5, 57.6) 57.8 (52.7, 64.6) 0.0066
Disease duration (years) 12.7 (6.94, 18.7) 25.1 (10.6, 31.4) 0.116
Caucasian 16 (72.7%) 17 (94.4%) 0.072
Ethnic Origin 0.406
Caucasian 16 17
Black Caribbean 2 1
Pakistani 2 0
Chinese 1 0
Other 1 0
Waist circumference (cm) 83.5 (71.0, 91.0) 85.5 (76.0, 95.0) 0.596
Hip circumference (cm) 98.5 (88.0, 105) 93.0 (89.5, 104) 0.913
BMI (kg/m2) 25.4 (22.0, 29.1) 25.0 (21.3, 28.8) 0.568
Vitamin D Status
 25(OH)D (ng/ml) 13.1 (10.3, 16.5) 34.5 (30.8, 40.2) < 0.001
 PTH (pg/ml) 47.0 (38.0, 66.0) 37.0 (29.0, 50.0) 0.096
 Calcium 2.34 (2.24, 2.38) 2.36 (2.32, 2.42) 0.634
Vitamin D supplements 0.005
 None 14 6
 Low dose 8 5
 High dose 0 7
Risk Factors for Vitamin D Deficiency
 Self-reported photosensitivity 15 (68.2%) 7 (38.9%) 0.064
 Active sun avoidance 14 (63.6%) 10 (55.6%) 0.604
 High-factor sunblock use 12 (54.5%) 8 (44.4%) 0.525
 Covered arms/legs 9 (40.9%) 1 (5.60%) 0.010
 Covered face 0 0 —
 Malabsorption syndrome 0 0 —
SLE Disease Features
 No. ACR criteria 5 (4, 6) 5 (4, 6) 0.748
 Renal disease (ever) 7 (31.8%) 1 (5.60%) 0.039
 ANA positive (ever) 21 (95.4%) 16 (88.9%) 0.433
 Steroids OR immunosuppressant 13 (59.1%) 3 (16.7%) 0.006
Table 1.  Baseline characteristics of the vitamin D deficient and replete groups. Comparisons between the 
groups were made using Mann-Whitey U-tests for continuous data and the Chi-squared test for categorical 
data. P < 0.05 was considered to be statistically significant.
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This was a clinically stable population of SLE patients and as such there was no significant change in the 
SLEDAI score in either group (median change of 0 points in both groups). The changes in endothelial function 
were therefore independent of SLE disease activity.
Discussion
Cardiovascular disease remains an important cause of morbidity and mortality both in patients with SLE and 
other inflammatory diseases. Endothelial repair is a recently recognised phenomenon in which damaged vas-
culature is restored by circulating populations of cells including MACs. In chronic disease states, defects in the 
number or function these pro-angiogenic myeloid cells are associated with both prevalent CVD and an increased 
risk of a cardiovascular event28,29. Other groups have shown that SLE patients have fewer MACs, which display 
impaired global function related in part to the presence of increased levels of IFNα 7,9,30,31.
We have shown that CFUs from SLE patients were both fewer and smaller than in healthy subjects, represent-
ing a global impairment of MAC function, supporting the data by Moonen et al.30. However, this is the first study 
to show increased MAC numbers in SLE, which may be a compensatory change, as SLE MACs exhibit impaired 
function in terms of migration and angiogenic capacity. Importantly, this study shows that SLE MACs demon-
strate impaired migratory capacity towards SDF-1α in vitro which may contribute to the impaired endothelial 
repair reported in this patient group. This is of interest as Wong et al. (2014) reported that calcitriol increased in 
re-endothelialisation and angiogenesis in murine models of endothelial damage. In these experiments, the hom-
ing of MACs to sites of vessel injury was SDF-1α -dependent25.
Myeloid cells are known to express functional VDRs and respond to calcitriol in vitro24. During the early 
stages of PBMC culture, we demonstrate a transient increase in the expression of the VDR before returning to 
basal levels, suggesting that MAC phenotype and/or function may be modified by local calcitriol concentrations 
during the onset of myeloid cell differentiation into MACs. It is not clear whether this change in VDR expression 
occurs within individual cells (thus changing their sensitivity to vitamin D) or represents a global shift in the 
myeloid cell phenotype during differentiation. The phenotype of SLE MACs was abnormal but was modified by 
calcitriol resulting in the normalisation of cell surface markers. Our observation that IL-6 production by MACs 
was reduced by calcitriol supports mRNA data from PBMCs26 and is of potential clinical relevance given the 
increased risk of CVD mortality associated with raised levels of IL-632. Although the change in surface makers 
and reduced IL-6 expression suggests that disease activity may be modified by calcitriol, this has not yet been 
demonstrated. In the randomised controlled trial by Aranow et al. (2015), cholecalciferol supplementation did 
not reduce expression of the IFN signature33. In this study, only 16/33 patients receiving vitamin D were replete 
Figure 6. Vitamin D improves endothelial function in SLE patients. (a) The change in serum 25(OH)D 
was strongly inversely correlated with the baseline 25(OH)D (treated patients only). (b) The number of MACs 
significantly increased over 3 months in the treated patients but not the control group. (c) There was a non-
significant increase in endothelial function (ED/EI) in the treated group but not the control group. The HC 
group (n = 9) is shown for comparison. (d) The change in endothelial function correlated with the change in 
25(OH)D in the treated group but not in the replete cohort. The Spearman correlation coefficient for each group 
is shown. Results show n = 22 deficient and n = 18 replete patients. *P < 0.05, by paired t tests
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by the end of the study period which may have significantly reduced the power of the study to detect a change in 
IFN pathway activation.
The angiogenic capacity of MACs is fundamental to their role in endothelial repair and we identified a number of 
pro- and anti-angiogenic factors differentially regulated by calcitriol in PBMCs. Amongst them, CXCL-10 (IP-10) 
has been reported to inhibit angiogenesis in a HUVEC Matrigel model27 and in vivo34. Furthermore, CXCL-10 
expression is regulated by IFNα and is expressed in the serum of SLE patients, and further increased during dis-
ease flare35,36. Our data therefore suggests that vitamin D may exert a vasculoprotective role in SLE by reducing 
MAC secretion of CXCL-10.
We did not investigate the effects of calcitriol in MACs from HCs beyond our IFN model. It remains uncertain 
if our observations are specific to SLE, or whether they represent a more general effect of calcitriol on MACs. 
We propose that further studies should determine whether similar observations are seen in healthy subjects and 
indeed other inflammatory diseases.
The number of MACs has previously been associated with endothelial function in SLE patients9. In our study, 
the number of MACs increased in SLE patients treated with cholecalciferol, but not in vitamin D replete control 
patients. Although the number of MACs isolated did not directly correlate with endothelial function, the change 
in ED/EI was strongly correlated with the change in 25(OH)D which may suggest that larger changes in vitamin D 
levels are needed. One potential mechanism, by which endothelial function may improve, is suggested by our 
observation that MACs reduced TNF-mediated eNOS down-regulation in endothelial cells and that this effect 
was augmented by calcitriol. A similar association between improvement in endothelial function in vivo and 
changes in eNOS expression in vitro has been demonstrated for other vasculoprotective drugs37,38.
Our finding that ED/EI improved after cholecalciferol replacement, and correlated with change in 25(OH)D 
levels, suggests a clinically relevant role for vitamin D on vascular health in SLE. However, in order to study clin-
ically relevant end-points, a formal clinical trial will be necessary. Our data also suggest that a threshold effect 
exists which warrants further study. Similarly, the dose, duration of effect and ideal target serum level of 25(OH)D 
for optimal vascular health may not necessarily be the same as those for bone health39. A recent pilot study by 
Kamen and Oates (2015) identified a similar effect of cholecalciferol supplementation on endothelial function in 
vitamin D deficient SLE patients40. Importantly, the authors reported that a target 25(OH)D of ≥32 ng/ml was 
needed for 50% of patients to show improvement in FMD, supporting the idea of a threshold effect. Finally, it is 
important to determine whether cholecalciferol treatment has any negative effects on vascular health in SLE. This 
population has a significant prevalence of CKD and some studies suggest that vitamin D may exacerbate hyper-
calcaemia and promote vascular calcification in this context41.
In conclusion, we have demonstrated that vitamin D can positively modulate endothelial function in patients 
with stable SLE, independently of disease activity, and that SLE MAC function is augmented by calcitriol in 
in vitro models. These observations support a role for vitamin D in improving cardiovascular health and reducing 
cardiovascular risk in SLE.
Methods
Subject recruitment. Clinically stable SLE patients were recruited from a single centre (Central Manchester 
University Hospitals) and healthy control subjects from the University of Manchester. Serum 25(OH)D was 
measured by liquid chromatography-mass spectroscopy (LC-MS). Vitamin D deficiency was defined as 25(OH)
D < 20 ng/ml and deficient patients were treated with high dose oral cholecalciferol (typically 400,000IU fol-
lowed by 20,000IU weekly) according to regional guidelines under the supervision of their usual physician in an 
observational manner. Vitamin D replete (<30 ng/ml) were not treated and acted as a control cohort. SLE disease 
activity was measured using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2 K) scor-
ing system.
Measurement of endothelial function. Endothelial function was measured by a single operator using 
flow-mediated dilatation (FMD) as described previously42. Briefly, subjects were fasted overnight and rested in 
a temperature-controlled room. A blood pressure cuff was placed on the forearm and inflated to supra-systolic 
pressure for 5 minutes. The brachial artery was visualised using a Philips iU-22 ultrasound machine and the 
diameter was measured off-line on a frame-by-frame basis for a period of 2 minutes. The mean maximal diam-
eter was calculated using a cubic spline curve. FMD was defined as the % change in diameter between baseline 
and mean maximal diameter. Dilatation was also measured in response to sublingual glyceryl trinitrate (GTN). 
Endothelial function was expressed as the ratio of endothelial-dependent (FMD) to endothelium-independent 
(GTN-mediated) dilatation (ED/EI) in order to correct for differences in baseline arterial diameter and subject age.
MAC isolation from whole blood. MACs were isolated by density separation of 50 ml whole blood in 
EDTA on Ficoll-paque PLUS (GE Healthcare Life Sciences, UK). PBMCs were cultured at a density of 1 × 106 
cells/cm2 in endothelial cell media with 20% FCS (EGM, Lonza, Switzerland) on human fibronectin for 7 days. 
Culture media was changed on day 4. The MAC phenotype was confirmed by Dil-Ac-LDL uptake and UEA-1 
lectin binding as described previously7. For functional assays MACs were used after 7 days and conditioned 
media obtained at the same time point. SLE MACs were also cultured in the presence of 1, 25(OH)2D3 (MAC-D).
Colony Forming Unit (CFU) assay. The CFU assay was performed in a separate SLE and healthy control 
cohort and was adapted from that reported by others29,43 PBMCs were isolated from 20 ml EDTA blood as described 
above. PBMCs were suspended in EGM-2 (with 20% FCS (Lonza, Switzerland) and plated at 2 × 106 cells/cm2  
onto human fibronectin-coated wells. After 48 hours, non-adherent cells were removed, washed, and re-plated 
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onto fibronectin. Cultures were maintained for a further 5 days. Colonies were enumerated manually and defined 
as a group of central rounded cells with peripheral spindle-shaped cells.
Adhesion assay. MAC adhesion to a TNFα -activated endothelial monolayer was measured. MACs were 
detached and labelled using Cell Tracker™ Green CMFDA (Molecular Probes, USA). Confluent monolayers of 
human aortic endothelial cells (HAoEC, Promocell, Germany) were treated for 6 hours with 10 ng/ml TNFα . We 
have previously demonstrated that this is sufficient to up-regulate expression of adhesion molecules in this cell 
type. MACs were allowed to adhere to the HAoECs for 1 hour, non-adherent cells removed, and the number of 
MACs quantified in random fields. Relative adhesion was expressed and the mean number of cells adherent to 
TNFα -activated HAoECs compared to resting endothelial cells.
Migration assay. The migration of MACs towards SDF-1α was determined by Transwell® migration assays. 
MAC and MAC-D were serum and growth factor-starved for 3 hours and then detached and re-suspended in 
basal EBM + 1% (w/v) bovine serum albumin. 1 × 106 cells were added to each fibronectin-coated Transwell® 
chamber (8 μm pore size) and allowed to migrate towards 100 ng/ml SDF-1α or EBM alone for 8 hours. The upper 
surface of the membrane was scraped clean and inserts were fixed in 100% ice-cold methanol overnight. Migrated 
MACs were stained with Mayer’s Heamulum for 5 minutes, mounted onto glass slides and the number of MACs 
was enumerated in 3 random fields per insert. The relative migration was expressed as the number of migrated 
cells in chambers containing SDF-1 compared to EBM alone.
Matrigel™ network formation assay. Network formation assays were used to determine the angiogenic 
capacity of MAC and MAC-D. 3.5 × 103 HAoECs were plated onto growth factor-reduced Matrigel™ in Ibidi 
μ-angiogenesis slides, in MAC or MAC-D conditioned media. Endothelial media (EGM) (± 10 nM 1, 25(OH)2D3) 
was used as a control. HAoEC networks were allowed to form for 14 hours and a single image obtained from each 
well. Networks were quantified in terms of the number of closed loops and the total pixel area (see supplementary 
methods).
Real-time PCR analysis. RT-PCR was performed using RNA obtained from PBMCs, MACs and HAoECs. 
RNA was isolated from PBMCs, MAC/MAC-D and HAoECs using the phenol-cholorform method with DNase 
1 (Ambion, UK) to remove genomic DNA. 1 μg RNA was reverse transcribed using the Precision nanoscript™ 
Reverse transcription kit (PrimerDesign Ltd, UK) according to the manufacturer’s protocol. Real-time qPCR 
was conducted using the SYBR green method on a 7500 Fast Real-Time PCR System (Applied Biosystems, UK). 
All PCR reactions were conducted using the Precision™ Mastermix with low ROX (PrimerDesign Ltd, UK). All 
primers were obtained from PrimerDesign (see supplementary Table). Gene expression was normalised to the 
geometric mean of CYC1 and ATP5B using the 2-ΔCt calculation.
Immunoblotting. Protein lysates from MACs and HAoECs were resolved on SDS-PAGE and transferred to 
nitrocellulose for blotting. In MACs antibodies against VDR (sc-13133, Santa Cruz, USA) and GAPDH (5174, 
Cell Signalling USA) were used. In HAoECs antibodies against eNOS (Cell Signalling, USA) and α -tubulin (Cell 
Signalling, USA) were used. HRP-conjugated secondary antibodies were obtained from Jackson Immunoresearch, 
USA.
MAC expression of IL-6 and CXCL-10. Cytokines in MAC-conditioned media were measured by colori-
metric ELISA using the IL-6 Human ELISA kit (Abcam, UK) and Human CXCL-10/IP10 ELISA kit (Invitrogen, 
USA) respectively, according to the manufacturer’s instructions.
Statistical methods. Patient-level data were compared using the Mann-Whitney U test (and Spearman’s 
correlation), whilst data from in vitro models were compared using either a two-tailed t test or paired t test as 
appropriate. The laboratory data is presented as mean ± SEM (unless described otherwise) of n ≥ 3 independent 
experiments. P < 0.05 was considered to be statistically significant.
Study approval. The study was approved by North West 1 Research Ethics Committee (11/NW/0008). All 
study participants provided written informed consent. The study conforms to the tenets of the Declaration of 
Helsinki.
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